



BAL PHARMA LIMITED
 Regd. Office: 21-22 Bommasandra Industrial Area, Anekal Taluq, Bangalore 560 099
UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31.12.2013

(Rs.in Lakhs)

Sr. No.	Particulars	Quarter Ended			Nine Months Ended		Year ended
		Unaudited			Unaudited		Audited
		31.12.2013	30.09.2013	31.12.2012	31.12.2013	31.12.2012	31.03.2013
1	Net Sales/Income from operations (Net of Excise Duty)	4,327.62	4,675.55	3,446.57	12,679.33	10,274.73	14,430.36
	Other Operating Income	97.51	109.10	89.55	300.66	234.84	361.08
	Net Income from Sales/Services	4,425.13	4,784.65	3,536.12	12,979.99	10,509.57	14,791.44
2	Expenditure						
	a) Increase/decrease in stock in trade and WIP	(13.28)	61.03	151.85	(11.13)	144.23	244.71
	b) Consumption of Raw Materials/ Packing Material	2,219.71	2,478.25	1,500.15	6,476.64	5,090.80	7,209.61
	c) Purchase of Stock in Trade	144.79	152.01	152.78	371.37	318.52	440.16
	d) Employee Cost	714.15	698.05	599.47	2,067.50	1,769.24	2,357.48
	e) Depreciation and amortisation expenses	110.63	109.36	102.13	372.25	297.56	481.22
	f) Other Expenditure	905.49	945.25	701.57	2,728.70	2,041.79	2,817.61
	g) Total	4,081.49	4,443.95	3,207.95	12,005.33	9,662.14	13,550.78
3	Profit from Operations before other Income, interest and Exceptional items(1-2)	343.64	340.70	328.17	974.66	847.43	1,240.66
4	Other Non-operating Income	4.61	14.91	6.60	27.42	29.74	65.93
5	Profit before Interest and Exceptional items (3+4)	348.25	355.61	334.77	1,002.08	877.17	1,306.59
6	Finance Costs	177.36	174.55	191.96	533.90	597.13	797.68
7	Profit after Interest but before Exceptional items	170.89	181.06	142.81	468.18	280.04	508.91
8	Exceptional items	-	-	-	-	-	-
9	Profit/Loss from ordinary activities Before Tax (7-8)	170.89	181.06	142.81	468.18	280.04	508.91
10	Tax expenses	31.85	40.11	38.66	96.74	63.88	80.56
11	Net Profit /Loss from ordinary Activities after Tax	139.04	140.95	104.15	371.44	216.16	428.35
12	Extra ordinary items	-	-	-	-	-	-
13	Net Profit / Loss for the period	139.04	140.95	104.15	371.44	216.16	428.35
14	Paid-up Equity Share capital(face value of Rs 10 each)	1,057.36	1,057.36	1,057.36	1,057.36	1,057.36	1,057.36
15	Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year						2,948.22
16	EPS (in Rs.)						
	a) Basic & Diluted	1.32	1.33	0.99	3.51	2.04	4.05
A							
17	Public shareholding						
	- Number of Shares	5,142,086	5,142,086	5,142,086	5,142,086	5,142,086	5,142,086
	- Percentage of shareholding	48.63	48.63	48.63	48.63	48.63	48.63
18	Promoters & Promoter group Shareholding						
	a) Pledged / Encumbered						
	- Number of Shares	-	-	-	-	-	-
	- Percentage of shareholding	-	-	-	-	-	-
	b) Non-encumbered						
	- Number of Shares	5,431,538	5,431,538	5,431,538	5,431,538	5,431,538	5,431,538
	- Percentage of shareholding	51.37	51.37	51.37	51.37	51.37	51.37
B	Investor Complaints						
	Particulars				For 3 months ended 31.12.13		
	Pending at the beginning of the quarter				Nil		
	Received during the quarter				16		
	Resolved during the quarter				14		
	Pending at the end of the quarter				2		

Notes:

1. The above Un-Audited Financial results, as reviewed by the Audit Committee were approved by the Board of Directors at their meeting held on 12.02.2014.
2. The Statutory Auditors of the Company have conducted a limited review on Un-Audited Financial results of the company for the quarter ended 31.12.2013
3. After receiving the full consideration amount of Rs.21/- per equity share, the Board has allotted 5,37,764 equity shares of Rs.10 each to Anita Siroya, upon conversion of warrant.
4. As the company deals with single product i.e pharmaceuticals, segment wise figures are not furnished.
5. Previous year figures were regrouped/ rearranged where ever required.

By the order of the Board
For Bal Pharma Limited

Shailesh Siroya
Managing Director